Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK159797 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| GSK159797 (10, 15, and 20mcg) | EXPERIMENTAL | GSK159797 (10, 15, and 20mcg) |
| salbutamol | EXPERIMENTAL | salbutamol |
| salmeterol 50mcg | EXPERIMENTAL | salmeterol 50mcg |
| placebo | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| GSK159797 (10, 15, and 20mcg) | DRUG | GSK159797 (10, 15, and 20mcg) |
| salbutamol | DRUG | salbutamol |
| salmeterol 50mcg | DRUG | salmeterol 50mcg |
| placebo | DRUG | placebo |
| GSK159797 | DRUG | - |
Inclusion criteria: * Subjects with documented history of persistent asthma using corticosteroids at a total daily dose of 200 to 200mcg of FP or equivalent corticosteroid * Female subjects only using acceptable birth control method * Non-smokers * FEV1 between 60 and 90% predicted * Increase in FE...
GSK159797 is an investigational small molecule developed by GSK plc for chronic obstructive pulmonary disease (COPD), a respiratory condition. It has been studied in Phase 2 clinical trials. It is not described as an approved medicine and remains in clinical development.
GSK159797 has been studied for pulmonary disease, chronic obstructive, the respiratory condition commonly called COPD. Its clinical trials enrolled adults with COPD or asthma to assess safety and lung function. It is investigational and has not been established as a marketed treatment for COPD.
GSK159797 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 2 studies of the compound in patients with respiratory disease, including chronic obstructive pulmonary disease and asthma.
GSK159797 is in Phase 2 development. Two Phase 2 trials have been completed, and no trials are currently active. The studies together enrolled 74 participants. The drug is investigational and is not described as FDA approved.
GSK159797 has been studied in two completed Phase 2 trials: NCT00358488, which investigated repeat doses in asthmatic patients across Germany, the Netherlands, Russia, Sweden and the United Kingdom, and NCT00354666, which tested single doses for patient safety and lung function in mild to moderate asthma.